RxDoctor Payments Data

Francis Walsh, MD

Neurology · Martinsville, VANPI 1851382873

Payments from drug & device makers

$23,493in general payments, 2019–2025

Across 1,356 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Biogen$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Lundbeck LLC$1K
  • UCB, Inc.$1K
  • EMD Serono, Inc.$888
  • plus $13K from 54 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$2001%
  • Food & beverage$22,71297%
  • Education$2801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)254$3,238
Biogen97$2,231
Teva Pharmaceuticals USA, Inc.85$1,576
Lundbeck LLC51$1,052
UCB, Inc.59$1,041
EMD Serono, Inc.24$888
Lilly USA, LLC49$875
Argenx US, Inc.36$720
Sunovion Pharmaceuticals Inc.45$699
Otsuka America Pharmaceutical, Inc.57$682
Novartis30$682
Pfizer48$559
Supernus Pharmaceuticals, Inc.58$535
Mallinckrodt Hospital Products Inc.30$527
Amneal Pharmaceuticals LLC36$523
E.r. Squibb & Sons, L.L.C.8$491
SK Life Science, Inc.25$461
Avanir Pharmaceuticals, Inc.33$459
AstraZeneca(2 entities)28$420
Sanofi11$387
Kyowa Kirin, Inc.18$372
Neurelis, Inc.16$366
Neurocrine Biosciences, Inc.18$364
Upsher-smith Laboratories LLC15$345
Bristol Myers Squibb20$334
Amgen(2 entities)19$313
Eisai Inc.19$309
Sumitomo Pharma America, Inc.16$283
Acadia Pharmaceuticals Inc28$238
Harmony Biosciences LLC8$223
Axsome Therapeutics, Inc.9$220
TG Therapeutics, Inc.10$172
Impel Pharmaceuticals Inc.10$163
Genentech USA, Inc.9$152
Vanda Pharmaceuticals Inc.7$142
Biohaven Pharmaceutical Holding Company Ltd.6$128
Greenwich Biosciences, Inc.7$115
Jazz Pharmaceuticals Inc.7$113
Livanova USA, Inc.6$111
Inspire Medical Systems, Inc.2$106
Corium, LLC5$95
Catalyst Pharmaceuticals, Inc.4$93
MDD US Operations, LLC4$74
Biohaven Pharmaceuticals, Inc.3$72
Merck4$69
Avion Pharmaceuticals2$68
Banner Life Sciences, LLC3$65
Johnson & Johnson1$54
ANI Pharmaceuticals, Inc.2$40
Cycle Pharmaceuticals Inc2$40
Resmed Corp2$36
Sanofi-aventis U.S. LLC2$31
Philips North America LLC1$28
Xeris Pharmaceuticals, Inc.1$21
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$19
Impel Pharmaceuticals LLC1$17
Tonix Medicines, Inc.1$17
Acorda Therapeutics, Inc1$14
Tanabe Pharma America, Inc.1$14
Shionogi Inc1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,493 in reported general payments places this provider in the 75th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$260,529
Medicare patients
1,030
Services billed
5,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate16$148,561
FingolimodFingolimod Hcl12$54,968
XcopriCenobamate34$38,655
Nurtec OdtRimegepant Sulfate25$34,305
VraylarCariprazine Hcl23$32,808
BriviactBrivaracetam20$28,451
QuliptaAtogepant16$25,102
AptiomEslicarbazepine Acetate18$22,508
Aimovig AutoinjectorErenumab-Aooe24$22,180
FycompaPerampanel17$20,870
NuedextaDextromethorphan Hbr/Quinidine11$15,944
Memantine Hcl408$14,608
Dalfampridine ErDalfampridine37$13,973
Carbidopa-LevodopaCarbidopa/Levodopa287$9,104
Repatha SureclickEvolocumab11$6,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$2,231$148,56116 claims
AbbVieVraylar, Qulipta$3,238$57,90939 claims
SK Life Science, Inc.Xcopri$461$38,65534 claims
PfizerNurtec Odt$559$34,30525 claims
UCB, Inc.Briviact$1,041$28,45120 claims
Sunovion Pharmaceuticals Inc.Aptiom$699$22,50818 claims
Eisai Inc.Fycompa$309$20,87017 claims
Avanir Pharmaceuticals, Inc.Nuedexta$459$15,94411 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$523$2,76540 claims
Upsher-smith Laboratories LLCTopiramate$345$1,340112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 neurology providers in Virginia.

Other neurology in Martinsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →